Cardinal Health Announces Board Chair Transition and Outlook

Cardinal Health ( (CAH) ) has issued an announcement.

Cardinal Health, based in Dublin, Ohio, is a major distributor of pharmaceuticals and specialty products, a global manufacturer and distributor of medical and laboratory supplies, and a supplier of home-health and direct-to-patient products and services. The company also operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions for healthcare customers worldwide.

This diversified healthcare services and products portfolio positions Cardinal Health as a critical link in the medical supply chain, serving hospitals, pharmacies, laboratories and home-care providers. Its customer-centric model and focus on operational efficiency and innovation underpin its role as an infrastructure backbone for the healthcare industry.

Cardinal Health announced that long-serving director Gregory B. Kenny, a board member since 2007 and chairman since 2018, notified the company on March 17, 2026, of his decision to retire from the board, all committees and the chair role, effective March 20, 2026. The company emphasized that Kenny’s retirement was not due to any disagreement over operations, policies or practices.

Effective immediately following his retirement, the board appointed existing director Patricia A. Hemingway Hall as chair, highlighting her deep institutional knowledge, nearly seven-year tenure as head of the Governance and Sustainability Committee and prior experience as CEO of Health Care Service Corporation. The leadership transition underscores Cardinal Health’s emphasis on strong governance continuity as it pursues long-term value creation and strategic priorities.

The company credited Kenny with guiding Cardinal Health through significant transformation, including strategic portfolio evolution and operational improvement initiatives during his chairmanship. Management expressed confidence that Hemingway Hall will continue this trajectory as the board oversees ongoing execution of the company’s strategy.

Cardinal Health also said it will report third-quarter fiscal 2026 results on April 30, 2026, and reaffirmed its confidence in its fiscal 2026 outlook. The reaffirmation signals management’s continued positive view of operational and financial performance despite leadership changes at the board level.

The most recent analyst rating on (CAH) stock is a Buy with a $258.00 price target. To see the full list of analyst forecasts on Cardinal Health stock, see the CAH Stock Forecast page.

Spark’s Take on CAH Stock

According to Spark, TipRanks’ AI Analyst, CAH is a Outperform.

The score is driven primarily by strong technical momentum and a very positive earnings update with raised FY26 EPS guidance and broad-based profit growth. Financial performance is supported by large and growing free cash flow, but weighed down by balance-sheet risk (negative equity and meaningful debt). Valuation is a secondary headwind due to the higher P/E and low dividend yield.

To see Spark’s full report on CAH stock, click here.

More about Cardinal Health

Cardinal Health, based in Dublin, Ohio, is a major distributor of pharmaceuticals and specialty products, a global manufacturer and distributor of medical and laboratory supplies, and a supplier of home-health and direct-to-patient products and services. The company also operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions for healthcare customers worldwide.

This diversified healthcare services and products portfolio positions Cardinal Health as a critical link in the medical supply chain, serving hospitals, pharmacies, laboratories and home-care providers. Its customer-centric model and focus on operational efficiency and innovation underpin its role as an infrastructure backbone for the healthcare industry.

Cardinal Health announced that long-serving director Gregory B. Kenny, a board member since 2007 and chairman since 2018, notified the company on March 17, 2026, of his decision to retire from the board, all committees and the chair role, effective March 20, 2026. The company emphasized that Kenny’s retirement was not due to any disagreement over operations, policies or practices.

Effective immediately following his retirement, the board appointed existing director Patricia A. Hemingway Hall as chair, highlighting her deep institutional knowledge, nearly seven-year tenure as head of the Governance and Sustainability Committee and prior experience as CEO of Health Care Service Corporation. The leadership transition underscores Cardinal Health’s emphasis on strong governance continuity as it pursues long-term value creation and strategic priorities.

The company credited Kenny with guiding Cardinal Health through significant transformation, including strategic portfolio evolution and operational improvement initiatives during his chairmanship. Management expressed confidence that Hemingway Hall will continue this trajectory as the board oversees ongoing execution of the company’s strategy.

Cardinal Health also said it will report third-quarter fiscal 2026 results on April 30, 2026, and reaffirmed its confidence in its fiscal 2026 outlook. The reaffirmation signals management’s continued positive view of operational and financial performance despite leadership changes at the board level.

Average Trading Volume: 1,720,939

Technical Sentiment Signal: Buy

Current Market Cap: $48.91B

See more data about CAH stock on TipRanks’ Stock Analysis page.